Answers are grounded in this paper and cite their sources.
High grade neuroendocrine carcinoma of the breast (HGNCB) is an aggressive and rare primary breast malignancy. No standard management recommendations exist for this entity and they are managed similarly as traditional breast cancers. Here we present the first case of a 54 year old female with high grade neuroendocrine carcinoma of the breast managed non-surgically with concurrent chemoradiation. At the time of this publication, she is more than 8 years from diagnosis without evidence of recurrence.
No takes yet. Share an insight, caveat, or question.
Sudbeck et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: